Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02999230




Registration number
NCT02999230
Ethics application status
Date submitted
13/12/2016
Date registered
21/12/2016
Date last updated
1/10/2024

Titles & IDs
Public title
Probiotics That Moderate pH and Antagonize Pathogens to Promote Oral Health
Scientific title
Probiotics That Moderate pH and Antagonize Pathogens to Promote Oral Health
Secondary ID [1] 0 0
5R01DE025832-05
Secondary ID [2] 0 0
IRB201602471-N
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Dental Caries 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Normal oral and gastrointestinal development and function

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Caries Free 1.5% Arginine
Other interventions - Caries Free Placebo Sodium Fluoride
Other interventions - Caries Active 1.5% Arginine
Other interventions - Caries Active- Placebo Sodium Fluoride

Active comparator: Caries Free - Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Study toothpaste will be assigned.

Placebo comparator: Caries Free- Placebo - Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Marketed Toothpaste will be assigned.

Active comparator: Caries Active - Gums will be examined and caries assessment performed. On some visits Saliva and plaque will be collected. Study toothpaste will be assigned.

Placebo comparator: Caries Active- Placebo - Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Marketed Toothpaste will be assigned.


Other interventions: Caries Free 1.5% Arginine
Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.

Other interventions: Caries Free Placebo Sodium Fluoride
Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.

Other interventions: Caries Active 1.5% Arginine
Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.

Other interventions: Caries Active- Placebo Sodium Fluoride
Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Levels of the arginine deiminase system (ADS) in oral samples of healthy and caries-active subjects changes from baseline to week 2
Timepoint [1] 0 0
Changes from baseline to 2 weeks (Screening)
Primary outcome [2] 0 0
Levels of the arginine deiminase system (ADS) in oral samples of healthy and caries-active subjects changes from week 2 to week 4
Timepoint [2] 0 0
Changes from week 2 to week 4 (Baseline)
Primary outcome [3] 0 0
Levels of the arginine deiminase system (ADS) in oral samples of healthy and caries-active subjects changes from week 4 to week 8
Timepoint [3] 0 0
Changes from week 4 to week 8 (Washout)
Primary outcome [4] 0 0
Levels of the arginine deiminase system (ADS) in oral samples of healthy and caries-active subjects changes from week 8 to week 12
Timepoint [4] 0 0
Changes from week 8 to week 12 (Evaluation)
Primary outcome [5] 0 0
Levels of the arginine deiminase system (ADS) in oral samples of healthy and caries-active subjects changes from baseline to week 12.
Timepoint [5] 0 0
Changes from baseline to week 12 (Evaluation)
Secondary outcome [1] 0 0
Bacteria collected from oral samples of healthy and caries-active subjects changes from baseline to week 2
Timepoint [1] 0 0
Changes from baseline to week 2
Secondary outcome [2] 0 0
Bacteria collected from oral samples of healthy and caries-active subjects changes from week 2 to week 4
Timepoint [2] 0 0
Changes from week 2 to week 4
Secondary outcome [3] 0 0
Bacteria collected from oral samples of healthy and caries-active subjects changes from week 4 to week 8
Timepoint [3] 0 0
Changes from week 4 to week 8
Secondary outcome [4] 0 0
Bacteria collected from oral samples of healthy and caries-active subjects changes from week 8 to week 12
Timepoint [4] 0 0
Changes from week 8 to week 12
Secondary outcome [5] 0 0
Bacteria collected from oral samples of healthy and caries-active subjects changes from baseline to week 12
Timepoint [5] 0 0
Changes from baseline to week 12

Eligibility
Key inclusion criteria
* Twenty natural uncrowned teeth excluding third molars
* No contraindications to dental treatment
* Caries Free-(with no clinical evidence of past or present caries)
* Caries Active- (At least two active sites)
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Less than 20 teeth
* Systemic disease that can cause xerostomia
* Taking medication known to cause xerostomia
* Have been treated with antibiotics within the past 3 months
* Advanced periodontal disease
* Removable or fixed dental appliances
* Bleeding disorders or taking anticoagulant medications
* Immune compromised individuals
* Uses tobacco products
* Participation in another clinical study one week prior to the start of the washout period or during the study period
* Use of any flavored products, such as mint flavored candies and chewing gum, one week prior to or during the study
* Unwilling or unable to provide informed consent and follow plaque/saliva collection instructions

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/02/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
25/06/2020
Sample size
Target
Accrual to date
Final
170
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida

Funding & Sponsors
Primary sponsor type
Other
Name
University of Florida
Address
Country
Other collaborator category [1] 0 0
Government body
Name [1] 0 0
National Institute of Dental and Craniofacial Research (NIDCR)
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study will examine the mechanisms of action of probiotics and synbiotics for control of oral diseases, with a particular focus on exploring new strategies for caries prevention and treatment.
Trial website
https://clinicaltrials.gov/study/NCT02999230
Trial related presentations / publications
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed

Contacts
Principal investigator
Name 0 0
Marcelle Nascimento, DDS, MS PhD
Address 0 0
University of Florida
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02999230